瘤基因诱导的TIM-3连接体表达决定了小鼠对抗TIM-3疗法的敏感性
Nana Talvard-Balland1,2, Lukas M Braun1,3, Karen O Dixon4,5
1Department of Internal Medicine I, Faculty of Medicine and Medical Center.
The Journal of clinical investigation
|June 25, 2024
概括
向T细胞免疫球蛋白和含有粘素的分子3 (TIM-3) 通过改善T细胞功能,增强了小鼠的移植与白血病 (GVL) 作用. 这种方法在移植后治疗复发性急性髓性白血病 (AML) 方面表现有前途,而不会增加移植对宿主疾病.
科学领域:
- 免疫学 免疫学 免疫学
- 在瘤学瘤学.
- 移植 移植 移植 移植
背景情况:
- 白血病复发后异质造血细胞移植 (allo-HCT) 是死亡的一个重要原因.
- 含有T细胞免疫球蛋白和粘素的分子3 (TIM-3) 是一个潜在的标,用于调节allo-HCT中的免疫反应.
研究的目的:
- 调查针对TIM-3的有效性,以增强移植与白血病 (GVL) 的效果,并克服allo-HCT后白血病复发.
- 确定TIM-3表达在白血病细胞和T细胞在致癌突变和alo-HCT结果的背景下发挥的作用.
主要方法:
- 利用患有瘤原驱动突变的白血病小鼠模型来评估抗TIM-3抗体治疗疗效.
- 进行了体外和体内实验,涉及TIM-3阻断或CD8+T细胞和髓状细胞中的遗传删除.
- 在复发性急性髓性白血病 (AML) 的患者样本中分析了TIM-3和连接体表达.
主要成果:
- 反TIM-3抗体治疗改善了白血病小鼠的存活率,这些小鼠表现出瘤基因诱导的TIM-3连接体表达.
- 在CD8+ T细胞中TIM-3阻断或删除增强了T细胞激活,增殖,IFN-γ产生,细胞毒性和糖解,从而改善了GVL效应.
- 与抗PD-1和抗CTLA-4疗法不同,TIM-3向并没有加剧急性移植对宿主疾病 (aGVHD).
结论:
- 准TIM-3是一个有前途的策略,可以增强GVL的影响,并打击HCT后的AML复发.
- 抗TIM-3疗法在代谢和转录方面对T细胞进行重新编程,改善抗白血病活性,而不会增加aGVHD.
- 对抗TIM-3抗体的临床研究是有必要的,因为AML在HCT后复发的患者.
相关概念视频
02:43Mouse Models of Cancer Study
5.5K
Mice have long served as models for studying human biology and pathology because of their phylogenetic and physiological similarity with humans. They are also easy to maintain and breed in the laboratory, and hence, many inbred strains are now available for research. Studies on mice have contributed immeasurably to our understanding of cancer biology.
The development of transgenic, knockout, and knock-in mice has led to an exponential increase in their use as model organisms in research,...
The development of transgenic, knockout, and knock-in mice has led to an exponential increase in their use as model organisms in research,...
5.5K
01:27Tumor Immunotherapy
511
Immunotherapy is a treatment that boosts or manipulates the immune system to fight diseases, including cancer. For instance, by stimulating an immune response through vaccinations against viruses that cause cancers, like hepatitis B virus and human papillomavirus, these diseases can be prevented. Nonetheless, some cancer cells can avoid the immune system due to their rapid mutation and division. The immune response to many cancers involves three phases: elimination, equilibrium, and escape.
511